Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

NCT07187804 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Age-related Macular Degeneration (ARMD)
Choroidal Neovascularization
Anti-vascular Endothelial Growth Factor

Interventions

DRUG: Intravitreal faricimab injection

Sponsor

Kim's Eye Hospital